Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa
Condition: Healthy Volunteers (Meningococcal Infection) Interventions: Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine; Biological: Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine; Biological: Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine Sponsor: Sanofi Pasteur, a Sanofi Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 29, 2019 Category: Research Source Type: clinical trials
Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49
Condition: Meningococcal Infection (Healthy Volunteers) Interventions: Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine; Other: Blood sample Sponsor: Sanofi Pasteur, a Sanofi Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 29, 2019 Category: Research Source Type: clinical trials
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa
Condition: Healthy Volunteers (Meningococcal Infection) Interventions: Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine; Biological: Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine; Biological: Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine Sponsor: Sanofi Pasteur, a Sanofi Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 29, 2019 Category: Research Source Type: clinical trials
Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49
Condition: Meningococcal Infection (Healthy Volunteers) Interventions: Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine; Other: Blood sample Sponsor: Sanofi Pasteur, a Sanofi Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 29, 2019 Category: Research Source Type: clinical trials
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa
Condition: Healthy Volunteers (Meningococcal Infection) Interventions: Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine; Biological: Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine; Biological: Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine Sponsor: Sanofi Pasteur, a Sanofi Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 29, 2019 Category: Research Source Type: clinical trials
Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49
Condition: Meningococcal Infection (Healthy Volunteers) Interventions: Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine; Other: Blood sample Sponsor: Sanofi Pasteur, a Sanofi Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 29, 2019 Category: Research Source Type: clinical trials
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa
Condition: Healthy Volunteers (Meningococcal Infection) Interventions: Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine; Biological: Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine; Biological: Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine Sponsor: Sanofi Pasteur, a Sanofi Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 29, 2019 Category: Research Source Type: clinical trials
Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
Condition: Meningococcal Infection (Healthy Volunteers) Interventions: Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine; Biological: Meningococcal Group B Vaccine (Trumenba®); Biological: Meningococcal group B Vaccine (Bexsero®) Sponsor: Sanofi Pasteur, a Sanofi Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 10, 2019 Category: Research Source Type: clinical trials
